Bioalgorithms for individualized medicine

At Necenti we identify epigenomic signatures that allow for completely personalized prevention and treatment of disease.

Our platform

In the same way that a seed needs climactic conditions to mature into a plant, the onset of disease occurs only when a certain pre-disease environment has allowed it to develop. In order for this to happen, epigenetics, the process by which external and internal factors help determine which of our genes will be activated or deactivated, is essential. This field of study is vital in determining the context that precedes (or doesn´t precede) disease.
It is estimated that 71% of illness-related deaths worldwide are due to non-communicable diseases, almost all of which are linked to preventable risk factors. This is why we at Necenti Laboratories we are committed to revolutionizing the way disease is identified and treated in the field of preventative and personalized medicine.

After 10 years of researching the origin of disease, we have developed a groundbreaking biochemical algorithm that allows us to measure the epigenetic fingerprint at the molecular level, using only a blood or saliva sample. Thanks to this technology, our platform Necenti100TM precedes the development of disease by an average of 10 years, precisely measuring how severe its impact will be on patients if and when they begin to develop symptoms. This technology makes it possible to meticulously plan medical treatment, applying concrete and personalized measures specific to each individual, and allows the health care system to calculate the resources needed according to the degree to which the illness will affect certain populations.


Here you may find a list of publications, both ours and from other researchers, that link the influence of epigenetics in the progression of diseases, including COVID-19. These publications are key to understanding the true impact of the technology developed by Necenti Labs.


About us

Necenti Laboratories is a biomedicine spin-off based on biochemical algorithms. It stems from the work of Dr. Sergio Caja, whose research at the Pediatric Research Center of the University of Tampere (Finland) has centered on the early diagnosis of various diseases since 2010.



Founder and Sole Director



Parque Científico de la UV Catedrático Agustín Escardino 9, 46980, Paterna, Valencia

Sergio Caja

CEO and Co-Founder

Sergio has a double doctorate in Molecular Biology and Health Sciences. He has specialized as a researcher in the early diagnosis of different diseases, developing advanced biomedical research programs in centers such as the Pediatric Research Center of the University of Tampere (Finland), the National Center for Cardiovascular Research (CNIC) in Spain and the Champalinaud Foundation in Portugal.

José Antonio es licenciado y Doctor en Medicina por la Universidad de Valladolid. Además, es investigador en el grupo de Inmunología de las Mucosas del Departamento de Pediatría e Inmunología del Instituto de Biología y Genética Molecular (IBGM) de la Universidad de Valladolid. Ha trabajado como investigador y como clínico en hospitales y centros de investigación tales como el Centro Nacional de Biotecnología (CNB), perteneciente al CSIC, o los Laboratorios de Inmunogenética e Inmunología Clínica del Hospital Académico de la Universidad Libre de Ámsterdam. Actualmente es Profesor Titular del área de Inmunología de la Universidad de Valladolid, con plaza vinculada en el Servicio de Análisis Clínico del Hospital Universitario Rio Hortega de Valladolid (Genética Molecular).

Eduardo es Doctor en Medicina por las Universidades de Valladolid y Edimburgo (Escocia, Reino Unido).  En la actualidad, es Catedrático de Inmunología de la Universidad de Valladolid; Director del Departamento de Pediatría, Inmunología, Obstetricia-Ginecología, Nutrición-Bromatología, Psiquiatría e Hª de la Ciencia, y Coordinador del Grupo de Investigación Reconocido “Inmunidad de las mucosas y Alergia” del Instituto de Biología y Genética Molecular-IBGM (Universidad de Valladolid-CSIC). Ha formado parte del Grupo de elaboración del “Protocolo para el diagnóstico precoz de la enfermedad celíaca” del Ministerio de Sanidad, Servicios Sociales e Igualdad y SESCS (2018), y ha sido Presidente de la Sociedad Española de Enfermedad Celíaca-SEEC entre 2007 y 2015.

David es Doctor en Inmunología por la Universidad de Valladolid. En la actualidad es investigador principal “Ramón y Cajal” en el Instituto de Biología y Genética Molecular de la Universidad de Valladolid y el CSIC. Su área de especialización es el estudio de la inmunología de las mucosas humanas, lo que le ha permitido desarrollar su labor investigadora lugares como Holanda, Inglaterra o España. Actualmente coordina un grupo de investigación centrado en el estudio de la enfermedad inflamatoria intestinal, la enfermedad celíaca, y la respuesta inmune establecida frente a COVID-19

manuel fuertes

President of the Board of Directors

Manuel is a technology transfer expert by the University of Oxford and Global CEO at KIATT Group, where he specializes in evolving leading science and technology into world-changing businesses. Across Asia-Pacific, Europe and Middle East, he sits on the board of multiple companies in sectors such as biotechnology, AI, nanotechnology, airspace, robotics and engineering.

Ramón tisaire


Ramón has held executive positions in numerous international consulting firms, including KMPG Consulting, Deloitte Chicago and Unisys Consulting. He specializes in areas such as business growth, business transformation, value creation, capital raising and internationalisation, working with both large companies and new projects on the US, Latin American and European markets.

SOFía olivia calvo


Sofía Olivia Calvo is an expert in neuromechanics and has worked in the Department of Human Anatomy and Embryology at the Rey Juan Carlos University until 2012, where she coordinated multidisciplinary work teams in various research and development projects together with other universities and research centres. Sofía is an assistant within Kiatt Group and manager of the Future Living project.

CLARA hinchcliffe


Clara Hinchcliffe is a researcher and expert in neuroscience. Clara is Chief Innovation Officer of the company and is in charge of the public, political and institutional relations of the laboratories in Europe and the USA.